1-(3-tert-butyl-1-(3-nitrophenyl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea | 1160934-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-tert-butyl-1-(3-nitrophenyl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea
• 英文别名: RL34；1-[5-tert-butyl-2-(3-nitrophenyl)pyrazol-3-yl]-3-(4-chlorophenyl)urea
• CAS: 1160934-81-5
• 化学式: C₂₀H₂₀ClN₅O₃
• 分子量: 413.863
• InChiKey: QMJQHTTXRJIVJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-tert-butyl-1-(3-nitrophenyl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea 在 镍 、 氯化铵 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以62%的产率得到1-(1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea
  参考文献：
  名称：

  Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc

  摘要：

  The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments. Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance. Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed us to employ principles of structure-based design to develop these scaffolds into potent type II kinase inhibitors. One of these compounds, 3c (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc. Details gleaned from crystal structures revealed a key feature of a subset of these compounds, a surprising flexibility in the vicinity of the gatekeeper residue that allows these compounds to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.

  DOI：

  10.1021/jm9002928
• 作为产物：
  描述：

  对氯苯异氰酸酯 、 2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl-amine 以 二氯甲烷 为溶剂， 反应 12.0h， 以463 mg的产率得到1-(3-tert-butyl-1-(3-nitrophenyl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea
  参考文献：
  名称：

  Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors

  摘要：

  Kinase disregulation disrupts the intricate network of intracellular signaling pathways and contributes to the onset of diseases such as cancer. Although several kinase inhibitors are on the market, inhibitor selectivity and drug resistance mutations persist as fundamental challenges in the development of effective long-term treatments. Chemical entities binding to less conserved allosteric sites would be expected to offer new opportunities for scaffold development. Because no high-throughput method was previously available, we developed a fluorescence-based kinase binding assay for identifying and characterizing ligands which stabilize the inactive kinase conformation. Here, we present a description of the development and validation of this assay using the serine/threonine kinase p38alpha. By covalently attaching fluorophores to the activation loop of the kinase, we were able to detect conformational changes and measure the K(d), k(on), and k(off) associated with the binding and dissociation of ligands to the allosteric pocket. We report the SAR of a synthesized focused library of pyrazolourea derivatives, a scaffold known to bind with high affinity to the allosteric pocket of p38alpha. Additionally, we used protein X-ray crystallography together with our assay to examine the binding and dissociation kinetics to characterize potent quinazoline- and quinoline-based type II inhibitors, which also utilize this binding pocket in p38alpha. Last, we identified the b-Raf inhibitor sorafenib as a potent low nanomolar inhibitor of p38alpha and used protein X-ray crystallography to confirm a unique binding mode to the inactive kinase conformation.

  DOI：

  10.1021/ja902010p

文献信息

• Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds
  申请人：Rauh Daniel

  公开号：US20110212475A1

  公开（公告）日：2011-09-01

  The present invention relates to a kinase labeled at an amino acid having a free thiol or amino group, wherein said amino acid is naturally present or introduced in the activation loop of said kinase, with (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitor, a method of determining the kinetics of ligand binding and/or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.